Literature DB >> 2517053

Pharmacological actions and clinical use of fructus schizandrae.

G T Liu.   

Abstract

Fructus Schizandrae (FS) is a well-known Chinese herb which has been widely used in ancient China. During recent decades, it has been found to be effective in viral and chemical induced hepatitis. In this paper, we report the studies on the chemical constituents and pharmacological actions of FS on mice liver. The results indicated that FS and its several components can mainly protect liver from injury induced by toxic substances such as CCl4; they have anti-oxidant activities against oxygen free radicals; FS and four components have inducing action on liver cytochrome P-450; they also promote certain anabolic metabolism such as serum protein biosynthesis and glycogenesis. All these activities would be of importance in the protection and repair of the injured liver cells. The clinical use of FS is also presented.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2517053

Source DB:  PubMed          Journal:  Chin Med J (Engl)        ISSN: 0366-6999            Impact factor:   2.628


  18 in total

1.  SCP, a polysaccharide from Schisandra chinensis, induces apoptosis in human renal cell carcinoma Caki-1 cells through mitochondrial-dependent pathway via inhibition of ERK activation.

Authors:  Shi-Jian Liu; Hai-Ming Qu; Ye-Ping Ren
Journal:  Tumour Biol       Date:  2014-02-07

2.  Schisandrol B protects against acetaminophen-induced hepatotoxicity by inhibition of CYP-mediated bioactivation and regulation of liver regeneration.

Authors:  Yiming Jiang; Xiaomei Fan; Ying Wang; Pan Chen; Hang Zeng; Huasen Tan; Frank J Gonzalez; Min Huang; Huichang Bi
Journal:  Toxicol Sci       Date:  2014-10-14       Impact factor: 4.849

3.  In vitro hepatoprotective and antioxidant activities of crude extract and isolated compounds from Ficus gnaphalocarpa.

Authors:  Donfack J Hubert; Amadou Dawe; Ngueguim T Florence; Kapche D W F Gilbert; Tchana N Angele; D Buonocore; P Vita Finzi; G Vidari; Ngadjui T Bonaventure; Fulvio Marzatico; Moundipa F Paul
Journal:  Inflammopharmacology       Date:  2010-11-19       Impact factor: 4.473

Review 4.  Selective tumor killing based on specific DNA-damage response deficiencies.

Authors:  Michael Biss; Wei Xiao
Journal:  Cancer Biol Ther       Date:  2012-03-01       Impact factor: 4.742

5.  Antioxidant therapy for chronic hepatitis C after failure of interferon: results of phase II randomized, double-blind placebo controlled clinical trial.

Authors:  Ezra Gabbay; Ehud Zigmond; Orit Pappo; Nila Hemed; Mina Rowe; George Zabrecky; Robert Cohen; Yaron Ilan
Journal:  World J Gastroenterol       Date:  2007-10-28       Impact factor: 5.742

6.  Schisandrin B down-regulated lncRNA BCYRN1 expression of airway smooth muscle cells by improving miR-150 expression to inhibit the proliferation and migration of ASMC in asthmatic rats.

Authors:  Xiao-Yu Zhang; Xue-Yi Tang; Li-Jun Ma; Ya-Li Guo; Xiao-Su Li; Li-Min Zhao; Cui-Jie Tian; Dong-Jun Cheng; Zhuo-Chang Chen; Luo-Xian Zhang
Journal:  Cell Prolif       Date:  2017-09-27       Impact factor: 6.831

7.  Intravenous injection of saeng maek san - a safe method of treatment in rats.

Authors:  Min-Ji Choi; Sung-Chul Kim; Seung-Hun Cho
Journal:  J Pharmacopuncture       Date:  2014-06

8.  Inhibition of ATR protein kinase activity by schisandrin B in DNA damage response.

Authors:  Hiroshi Nishida; Naoto Tatewaki; Yuki Nakajima; Taku Magara; Kam Ming Ko; Yasuo Hamamori; Tetsuya Konishi
Journal:  Nucleic Acids Res       Date:  2009-07-22       Impact factor: 16.971

9.  Therapeutic efficacy of traditional Chinese medicine, Shen-Mai San, in cancer patients undergoing chemotherapy or radiotherapy: study protocol for a randomized, double-blind, placebo-controlled trial.

Authors:  Lun-Chien Lo; Chia-Yun Chen; Shou-Tung Chen; Hung-Chang Chen; Tsung-Chieh Lee; Cheng-Shyong Chang
Journal:  Trials       Date:  2012-12-03       Impact factor: 2.279

10.  Antiproliferative and apoptosis-inducing activity of schisandrin B against human glioma cells.

Authors:  Qun Li; Xiang-He Lu; Cheng-de Wang; Lin Cai; Jiang-Long Lu; Jin-Sen Wu; Qi-Chuan Zhuge; Wei-Ming Zheng; Zhi-Peng Su
Journal:  Cancer Cell Int       Date:  2015-02-04       Impact factor: 5.722

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.